Abstract
Background This study estimated the effects of the SARS-CoV-2 pandemic on maternal death causes in Chile during the outbreak peak between 2020 and 2021.
Materials and Methods A natural experiment was conducted using official data on maternal deaths and live births (LBs) between 1997 and 2021. Trend changes in the maternal mortality ratio (MMR) were assessed using segmented regression. The effects of the SARS-CoV-2 outbreak were evaluated using interrupted time series (ITS) and an autoregressive integrated moving average (ARIMA) model to forecast the expected rates on MMR and 95% confidence intervals (95% CI).
Findings ITS analysis revealed that the SARS-CoV-2 outbreak impacted the MMR due to indirect causes, with a greater increase in indirect nonrespiratory causes than respiratory causes. The ARIMA forecast was consistent with ITS, showing that the expected MMR for indirect causes was substantially lower than the observed rates (9.65 in 2020 and 7.46/100,000 LBs in 2021). The expected MMR was 3.44 in 2020 and 1.55 in 2021. For nonrespiratory causes, the observed values of the MMR for 2020 (8.77/100.000 LBs) and 2021 (7.46/100.000 LBs) doubled the prediction 4.02 (95% CI: 0.44-7.61) and 3.83 (95% CI: -0.12-7.79). No significant effect was found on direct obstetrical deaths.
Interpretation During 2020-2021, there was a rise in the MMR in Chile attributable to SARS-CoV-2. The pandemic contributed to an escalation in the MMR due to indirect causes, particularly nonrespiratory and infectious causes, suggesting that the risk of pregnant women to SARS-CoV-2 was increased from previous comorbidities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by research grants EPI-092018-01 and ONE-052021-01, both granted by FISAR http://www.fisarchile.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This was a secondary data analysis of publicly available information. The source of the information is the official anonymous maternal mortality records of Chile published by the DEIS (available at https://deis.minsal.cl/). The study protocol was approved by the Ethics Committee of the Catholic University Sedes Sapientiae, Lima, Peru.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding This study was supported by FISAR.
Data Availability
The data underlying this article is available from Departamento de Estadísticas de Información de Salud del Gobierno de Chile, https://deis.minsal.cl/. The derived data generated in this research will be shared on reasonable request to the corresponding author.
